AOD-9604.

GH fragment (177-191) — targets lipolysis without systemic GH effects.

Select strengthPer-vial price

Quantity

Total

€50.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
✓Patient-named prescription only — dispensed against a valid Rx.
✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
✓Cold-chain shipping across EU/EEA — 2–5 working days.

Overview

About AOD-9604.

AOD-9604 is a synthetic peptide corresponding to the lipolytic C-terminal fragment (residues 177-191) of human growth hormone. It was developed in the 1990s as a way to capture the fat-mobilising activity of GH without its growth and glucose effects.

The clinical evidence base is mixed — some studies show modest fat-loss effects, others show no separation from placebo. AOD-9604 is generally used as an adjunct rather than a primary intervention.

Mechanism of action

AOD-9604 binds beta-3 adrenergic receptors on adipocytes, stimulating lipolysis. It does not bind the GH receptor, which explains the absence of GH-mediated effects on muscle, bone or glucose metabolism.

Posology · for information only

Subcutaneous injection, typically 300 mcg once daily in the morning before activity or fasting periods.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence baseClinical case-series evidence

Indications studied

Lipolysis supportAdjunct in body-composition protocols

Identification & specifications

INN / Name: AOD-9604
Form: Lyophilised vial · subcutaneous injection
Strength: 5mg vial
Manufacturing: EU-GMP Annex 1 · Grade A/B
Endotoxins: European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity: HPLC + MS · > 98%
Cold chain: Validated 2–8 °C, monitored end-to-end
Regulatory basis: Directive 2001/83/EC · Article 5(1)

Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Weight Management.

All Weight Management preparations